Preferred Label : Lutetium Lu 177-DOTA-EB-TATE;
NCIt synonyms : Lutetium Lu 177-DOTA-EB-Tyr3-Octreotate; 177 Lu-DOTA-EB-TATE; Lutetium Lu 177 DOTA(0)-EB-Tyr(3)-Octreotate; 177Lu-DOTA0-EB-Tyr3-Octreotate; Lutetium-177-DOTA-EB-TATE; Lutetium-177-1, 4, 7, 10-tetra-azacyclododecane-1, 4, 7, 10-tetraacetic acid-Evans
blue-octreotate; (177)Lu-DOTA-EB-TATE; 177Lu-DOTA-EB-TATE;
NCIt definition : A radioconjugate consisting of Evans blue (EB) modified, tyrosine-containing somatostatin
analog, Tyr3-octreotate (TATE), conjugated with the bifunctional, macrocyclic chelating
agent tetra-azacyclododecane tetraacetic acid (DOTA), and radiolabeled with the beta-emitting
radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intravenous
administration, lutetium Lu 177-DOTA-EB-TATE binds to somatostatin receptors (SSTRs),
specifically with high affinity to type 2 SSTRs (SSTR2s), present on the cell membranes
of many neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate
specifically delivers a cytotoxic dose of beta radiation to SSTR2-positive cells.
The incorporation of an albumin-binding moiety through EB modification allows lutetium
Lu 177-DOTA-EB-TATE to reversibly bind to endogenous albumin, potentially extending
half-life and increasing targeted accumulation of the drug in tumors. SSTRs, especially
SSTR2s, are expressed at relatively higher levels in many tumor cell types and tumor
blood vessels, compared to normal tissues.;
NCI Metathesaurus CUI : CL555349;
Origin ID : C154549;
UMLS CUI : C4733609;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
